Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.805
+0.1051.21%
Volume:55.66M
Turnover:489.54M
Market Cap:101.45B
PE:22.17
High:8.850
Open:8.820
Low:8.685
Close:8.700
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.45
T/O Rate:0.48%
Dividend:0.34
Dividend Rate:3.83%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.31
PE(LYR):22.17
PS:2.77

Loading ...

CSPC Pharma Gains Chinese Clinical Trial Approval for Goserelin Extended-Release Injection

Stock News
·
Sep 09

CSPC Pharma Wins China Clinical Trial Clearance for Syh9102 Goserelin Injection

Reuters
·
Sep 09

CSPC Pharmaceutical - Goserelin Sustained-Release Injection (Syh9102 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Sep 09

Movement Alert|CSPC PHARMA Falls 3.03% in Regular Trading, Global Market Selloff Drags Down Pharmaceutical Sector

Market Focus
·
Sep 09

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

MT Newswires Live
·
Sep 08

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

Reuters
·
Sep 08

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS
·
Sep 08

CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 08

Market Bets on BOJ Rate Hike While CICC's Merger Wins Regulatory Approval

Stock News
·
Sep 08

CSPC Pharma Begins Phase II Study of Influenza Drug in China

MT Newswires Live
·
Sep 07

Fourth Breakthrough Therapy Designation Granted to EGFR-Targeted ADC Developed by CSPC

Deep News
·
Sep 07

CSPC Pharma Initiates Phase II Trial of SYH2085 Tablet for Uncomplicated Influenza in Chinese Adults

Stock News
·
Sep 07

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Dow Jones
·
Sep 03

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03

Movement Alert|CSPC PHARMA Rises 3.11% in Regular Trading, Multiple Pipeline Milestones Drive Momentum

Market Focus
·
Sep 03

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Reuters
·
Sep 01

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live
·
Sep 01

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live
·
Sep 01

CSPC Pharma Launches Phase I Trial of Novel 5-HT2A Partial Agonist SYH2056 for Depression in China

Bulletin Express
·
Sep 01

CSPC Pharma Secures Third NMPA Breakthrough Therapy Designation for EGFR-Targeting ADC SYS6010 in Recurrent/Metastatic Head-and-Neck Cancer

Bulletin Express
·
Sep 01